Barclays transferred coverage of Clovis (CLVS) to Gena Wang, who set an Overweight rating on the stock with a $58 price target. Barclays previously had an Overweight rating on the name. Both Tesaro (TSRO) and Clovis have pulled back after initial enthusiasm on the PARP inhibitors as a drug class in oncology, but Wang still sees great potential for PARPi to penetrate broader cancer indications and believes the collective global market opportunity is large enough for multiple players. Wang said she sees a good chance for Rubraca monotherapy to show positive data in Q3 in prostate cancer for potential accelerated approval.